Asia CAR-T cell therapy
繁體中文As of 2026-11-01, Drugnews tracks 7 Asian programs in CAR-T cell therapy across Korea and Taiwan; the most advanced is AT101 (nespecabtagene autoleucel) from AbClon Inc. (Phase 2 interim results (May 2025 milestone)).
Companies
- AbClon Inc.
- PELL BMT
- UWELL
Assets
| Company | Country | Code | Asset | Mechanism | Stage | Indication | Partner | Deal terms | Sources |
|---|---|---|---|---|---|---|---|---|---|
| AbClon Inc. | Korea | AT101 | AT101 (nespecabtagene autoleucel) | CAR-T | Phase 2 interim results (May 2025 milestone) | — | — | — | 2025-05 |
| PELL BMT | Taiwan | PL001 | PL001 | CD19 CAR-T | Phase 1 / Phase 2; active not recruiting | Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Large B-cell Lymphoma; Follicular Lymphoma Grade 3A; Follicular Lymphoma Grade 3B | — | — | 2026-10-09 |
| PELL BMT | Taiwan | PL002 | PL002 | 間皮素多鏈CAR-T | Preclinical | — | — | — | 2026-05-27 |
| PELL BMT | Taiwan | PL003 | PL003 | BCMA CAR-T | Preclinical | — | — | — | 2026-05-27 |
| PELL BMT | Taiwan | PL004 | PL004 | in vivo CAR-T | Preclinical | — | — | — | 2026-05-27 |
| UWELL | Taiwan | UWFAP | UWFAP | FAP CAR-T | Preclinical | — | — | — | 2026-01-15 |
| UWELL | Taiwan | UWN2D | UWN2D | NKG2D CAR-T | Preclinical | — | — | — | 2026-01-15 |
No matches. Clear the search to show all assets.
Outbound licensing deals
No source-linked licensing records are present in this input snapshot.
FAQ
How many Asian CAR-T cell therapy programs are tracked?
The November 1, 2026 table contains 7 programs in 3 company groups, across Korea and Taiwan.
Which program is the most advanced?
AT101 (nespecabtagene autoleucel) from AbClon Inc. is listed as Phase 2 interim results (May 2025 milestone). This is the highest source-dated stage in this table, shared by 2 programs; stages and dates are shown for each asset.
What does this page cover?
The table covers CAR-T programs from Korea and Taiwan. No iPSC program is included in this snapshot. Source-dated stages do not establish that every trial is currently active.
Which Taiwanese programs are included?
PL001 (Phase 1 / Phase 2; active not recruiting); PL002 (Preclinical); PL003 (Preclinical); PL004 (Preclinical); UWFAP (Preclinical); UWN2D (Preclinical).
How many Asian outbound licensing events are listed?
The table contains 0 published licensing events. Upfront payments and potential total values are separate; this snapshot does not establish that no deals exist.